相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies
Vid Stanulovic et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials Comment
Ethan Basch et al.
CLINICAL TRIALS (2022)
Evaluation of the patient experience of symptomatic adverse events on Phase I clinical trials using PRO-CTCAE
Geoffrey A. Watson et al.
BRITISH JOURNAL OF CANCER (2022)
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
CLINICAL TRIALS (2021)
Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials
Zachary W. Veitch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials
Robert L. Coleman et al.
ONCOLOGY (2021)
Trends in patient-reported outcome (PRO) use in early phase oncology trials
J. E. Lai-Kwon et al.
ANNALS OF ONCOLOGY (2020)
Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials
Ramy Sedhom et al.
JNCI CANCER SPECTRUM (2020)
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library
Daniel Shepshelovich et al.
ONCOLOGIST (2019)
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Arlene E. Chung et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2019)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
What Do None, Mild, Moderate, Severe, and Very Severe Mean to Patients With Cancer? Content Validity of PRO-CTCAE (TM) Response Scales
Thomas M. Atkinson et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2018)
Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials
Peter C. Trask et al.
CLINICAL TRIALS (2018)
Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial
Ethan Basch et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety data
Ethan Basch et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Antonia V. Bennett et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2016)
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
Andrew Bottomley et al.
LANCET ONCOLOGY (2016)
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Amylou C. Dueck et al.
JAMA ONCOLOGY (2015)
Words or numbers? Communicating risk of adverse effects in written consumer health information: a systematic review and meta-analysis
Roland Brian Buechter et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2014)
Recommended Patient-Reported Core Set of Symptoms to Measure in Adult Cancer Treatment Trials
Bryce B. Reeve et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Ethan Basch et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Jennifer L. Hay et al.
QUALITY OF LIFE RESEARCH (2014)
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
Albert Deisseroth et al.
CLINICAL CANCER RESEARCH (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire
M. Cirillo et al.
ANNALS OF ONCOLOGY (2009)
Dose Escalation Methods in Phase I Cancer Clinical Trials
Christophe Le Tourneau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Patient-reported outcomes and the evolution of adverse event reporting in oncology
Andy Trotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30
EK Fromme et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
